Cysts of the adrenal gland are often misinterpreted and misdiagnosed because of their rarity. There are few reports in the literature of adrenal cyst in children, especially in the newborn. Adrenal cysts in the newborn are usually of the pseudocyst due to adrenal hemorrhage and have tendency to become adherent to surrounding structure, mimicking malignant tumor. We report a cases of pyogenic adrenal cyst in the newborn which was suspected malignancy because of adherence to adjacent organ.
Adrenal Glands ; Child ; Hemorrhage ; Humans ; Infant, Newborn*

BACKGROUND: Hepaitis A virus(HAV) infection occurs commonly during early childhood. Recent improvements in sanitation and hygiene have resulted in a decrease in HAV infection among children, while the clinical illness of hepatitis A and prevalence of antibody to HAV(anti-HAV IgG) have been increased, particularly in the 3rd decade of young male adults. We studied a seroepidemiology of anti-HAV IgG in combat policemen who were living together during their service in the combat police force. METHODS: We measured anti-HAV IgG(HAVAB, Abbott) from 1,009 healthy subjects with no history of transfusion of any blood products during the last 6 months. The mean age was 20.8 years. RESULTS: Overall, anti-HAV IgG was detected in 30.2% of study subjects. According to age, the positive rates of antibody were 15.7%, 25.9%, 31.5%, 38.1%, 43.5%, and 50.0% in 19, 20, 21, 22, 23, and 24 years respectively. The positive rates of anti-HAV IgG as to period of service were 17.3%, 28.1%, 40.9% in 0 month, 1-12 months, 13-24 months respectively. The positive rates of anti-HAV IgG were 27.0% in the urban group, 39.8% in the rural group. CONCLUSION: The positive rates of anti-HAV IgG in our data low compared with those of previous reports. We think that group living condition such as living in dormitories or barracks can be a risk factors for hepatitis A infection and that improvements to the sanitary system and active immunization would be necessary for prevention of it.
Adult ; Child ; Epidemiology ; Hepatitis A ; Hepatitis A Antibodies* ; Humans ; Hygiene ; Immunoglobulin G* ; Male ; Police ; Prevalence ; Risk Factors ; Sanitation ; Seroepidemiologic Studies* ; Social Conditions ; Vaccination

BACKGROUND/AIMS: The translocation of bacteria and their lipopolysaccharides from the gut can promote fibrosis in cirrhotic patients. The aim of this study was to investigate the effects of rifaximin on hepatic fibrosis in a bile duct-ligated rat model. METHODS: The bile duct ligation (BDL) was carried out for eight days (acute injury model: sham-operated rats [G1], BDL rats [G2], and BDL rats treated with rifaximin [G3]) or 22 days (chronic injury model: sham-operated rats [G4], BDL rats [G5], and BDL rats treated with rifaximin [G6]). Rifaximin (50 mg/kg/day) was administered daily via gavage after BDL. Liver function, serum tumor necrosis factor-alpha (TNF-α), and hepatic hydroxyproline levels were measured. Moreover, a histological analysis of fibrosis contents was performed using sirius red stain. RESULTS: In the acute injury model, the liver function and TNF-α level were not improved after the rifaximin treatment. The hydroxyproline levels (µg/g liver tissue) in G1, G2, and G3 were 236.4±103.1, 444.8±114.4, and 312.5±131.6, respectively; and fibrosis contents (%) were 0.22±0.04, 1.64±0.53, and 1.66±0.44, respectively. The rifaximin treatment did not ameliorate acute BDL-induced fibrosis. In the chronic injury model, the hydroxyproline levels in G4, G5, and G6 were 311.5±72.9, 1,110.3±357.9, and 944.3±209.3, respectively; and fibrosis contents (%) were 0.19±0.03, 5.04±0.18, and 4.42±0.68, respectively (G5 vs. G6, p=0.059). The rifaximin treatment marginally ameliorated chronic BDL-induced fibrosis. CONCLUSIONS: Rifaximin did not reduce inflammation and fibrosis in bile duct-ligated rat model.
Animals ; Bacteria ; Bile Ducts ; Bile* ; Fibrosis* ; Humans ; Hydroxyproline ; Inflammation ; Ligation ; Lipopolysaccharides ; Liver ; Liver Cirrhosis ; Models, Animal* ; Rats* ; Tumor Necrosis Factor-alpha

BACKGROUND/AIMS: Hepatitis C genotypes 1 and 2 are widely distributed globally. In contrast, genotype 6 is found mainly in Southeast Asia, while genotype 6 is rare in Korea. This study aims to investigate the prevalence, risk factors and clinical characteristics of patients with genotype 6 chronic hepatitis C. METHODS: We retrospectively identified 133 HCV-infected patients who underwent HCV genotype analysis between January 2012 and December 2012, and analyzed the prevalence, risk factors and clinical characteristics of patients diagnosed with genotype 6 chronic hepatitis C. RESULTS: Among 133 patients, 53 patients (39.8%) were infected with genotype 1, 62 patients (46.6%) with genotype 2, 2 patients (1.5%) with genotype 3, 14 patients (10.5%) with genotype 6, and 2 patients (1.5%) with mixed genotypes (genotype 1 and 6). The risk factors associated with genotype 6 were acupuncture (n=4, 28.6%), intravenous drug use (n=3, 21.4%), tattoo (n=2, 14.3%), and transfusion (n=2, 14.3%). Of the 14 patients with genotype 6, 6 patients were treated with pegylated interferon and ribavirin. Five patients had reached the end of treatment. All patients reaching end of treatment for genotype 6 showed early virological response and sustained virological response. CONCLUSIONS: The prevalence of genotype 6 is 10.5% and mixed infections of genotype 1 and 6 are 1.5% in patients with chronic hepatitis C. A major potential risk factor is intravenous drug use and the treatment response rate to pegylated interferon plus ribavirin is high in patients with genotype 6 chronic hepatitis C. Large scale multicenter studies are needed.
Acupuncture Therapy ; Adult ; Aged ; Antiviral Agents/therapeutic use ; Blood Transfusion ; Drug Therapy, Combination ; Female ; Genotype ; Hepacivirus/*genetics/isolation & purification ; Hepatitis C, Chronic/*diagnosis/drug therapy/epidemiology ; Humans ; Interferon-alpha/therapeutic use ; Male ; Middle Aged ; Polyethylene Glycols/therapeutic use ; Prevalence ; RNA, Viral/genetics ; Recombinant Proteins/therapeutic use ; Republic of Korea ; Retrospective Studies ; Ribavirin/therapeutic use ; Risk Factors ; Tattooing